16 April 2012

In this issue:

› Starpharma commences pivotal phase 3 VivaGel^® BV treatment trials

› Starpharma continues to build momentum as a leader in the sector

› Starpharma improves efficacy of leading chemotherapy drug docetaxel with dendrimers in breast cancer model

› Nanobiotechnology to reach $6 billion by 2017

 

Download: Shareholder Update: April 2012 ( pdf file, 1MB)

Read more

20 December 2011

In this issue:

› Starpharma raises $35m to advance pipeline

› Starpharma signs with Ansell for condom coating

› Putting a stop to stubborn BV: The VivaGel^© solution

› Clinical trials for VivaGel^© gather pace

› M&G invests $20 million

› Dendrimers through the eyes of Professor Donald Tomalia

 

Download: Shareholder Update: December 2011 (pdf file, 628kb)

Read more

26 July 2011

In this issue:

› VivaGel® demonstrates efficacy in the treatment of bacterial vaginosis; Independent study finds link between bacterial vaginosis and HIV

› Japanese VivaGel® condom deal secures second largest condom market in the world

› Starpharma’s Priostar dendrimers improve bestselling herbicide

› Drug delivery program delivers early-stage results in improving blockbuster chemo drug.

 

Download:  Shareholder Update: July 2011 ( pdf file, 1MB)

Read more